Sanofi Appoints New Chief Executive

- The new CEO, Belén Garijo, is a physician by training who previously spent 15 years at Sanofi, where she led the integration of Genzyme, before becoming the CEO of Merck KGaA. Her appointment is seen as a move to instill more "rigor" into executing strategy and to bolster R&D productivity, governance, and innovation, following a series of pipeline setbacks under the outgoing CEO, Paul Hudson. - A key challenge for the new leadership will be to navigate the patent expiration of the blockbuster immunology drug Dupixent, which accounted for approximately 36% of total revenues in 2024. This financial pressure underscores the urgency to improve the success rate of the late-stage pipeline and effectively integrate new technologies to accelerate development. - Sanofi is heavily invested in Industry 4.0 principles, with digitally-enabled manufacturing facilities that utilize continuous, paperless production with electronic batch records. At its Framingham, MA site, for example, sensors generate over 3 billion data points from 5,000 parameters for a standard batch, feeding into advanced data analytics to improve quality and yield. - The company is actively deploying "digital twins" to model and optimize manufacturing processes, notably at its new "EVolutive" vaccine facilities in France and Singapore. This technology allows for virtual simulation of production lines and process scale-ups, aiming to reduce facility qualification times from months to weeks and accelerate technology transfers. - To support its digital ambitions, Sanofi is building a robust data infrastructure focused on contextualized data, integrating plant-floor systems like MES and LIMS with cloud data foundations. This architecture is crucial for leveraging their AI-powered analytics platform, SimplY, which has already been used to identify an 8% increase in output for Dupixent drug substance. - In cell and gene therapy, Sanofi has strategically shifted its focus from autologous to "off-the-shelf" allogeneic cell therapies, marked by the acquisition of Kiadis. The company is leveraging its long-standing expertise in viral-based vaccine manufacturing to develop its own large-scale viral vector production capabilities. - Sanofi has established numerous partnerships to accelerate its AI capabilities in drug discovery and development. Collaborations with companies like Owkin, Atomwise, Insilico Medicine, and BioMap are aimed at using AI for target identification, designing biologics, and predicting clinical trial outcomes. - Outgoing CEO Paul Hudson drove the vision to become an "AI-powered biopharma company," increasing the R&D budget from €5 billion to €8.5 billion and rolling out an internal AI app called "plai" to over 20,000 employees to provide a 360° view of all company activities for data-driven decision making.